Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
NCT07149857

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Led by Janssen Research & Development, LLC · Updated on 2026-05-08

60

Participants Needed

17

Research Sites

183 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta-cel infusion following a cyclophosphamide and fludarabine lymphodepletion regimen.

CONDITIONS

Official Title

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 80 years
  • Documented diagnosis of newly diagnosed multiple myeloma with measurable disease at diagnosis
  • Not eligible for high-dose chemotherapy with stem cell transplantation due to advanced age, comorbid conditions, or refusal
  • Received at least 3 and no more than 5 cycles of induction therapy with DRd, VRd, or DVRd
  • Achieved partial response or better on most recent disease assessment
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
  • Willing and able to follow lifestyle restrictions in the protocol
Not Eligible

You will not qualify if you...

  • Frailty index of 2 or higher according to Myeloma Geriatric Assessment score
  • Known allergies, hypersensitivity, or intolerance to study treatments or their active agents
  • Grade 2 or higher ongoing non-hematologic toxicity from induction therapy, except grade 2 peripheral neuropathy due to bortezomib
  • Requirement for continuous supplemental oxygen

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 17 locations

1

University of California San Francisco

San Francisco, California, United States, 94143

Actively Recruiting

2

Moffitt Cancer Center

Tampa, Florida, United States, 33612

Active, Not Recruiting

3

University of Iowa Hospital and Clinics

Iowa City, Iowa, United States, 52242

Active, Not Recruiting

4

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Active, Not Recruiting

5

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Actively Recruiting

6

Royal Prince Alfred Hospital

Camperdown, Australia, 2050

Actively Recruiting

7

Austin Hospital

Heidelberg, Australia, 3084

Actively Recruiting

8

Fiona Stanley Hospital

Murdoch, Australia, 6150

Actively Recruiting

9

Princess Alexandra Hospital

Woolloongabba, Australia, 4102

Actively Recruiting

10

Hosp. Univ. Germans Trias I Pujol

Badalona, Spain, 08916

Actively Recruiting

11

Hosp Univ Vall D Hebron

Barcelona, Spain, 08035

Actively Recruiting

12

Hosp. Clinic de Barcelona

Barcelona, Spain, 08036

Actively Recruiting

13

Hosp. Univ. 12 de Octubre

Madrid, Spain, 28041

Actively Recruiting

14

Clinica Univ. de Navarra

Pamplona, Spain, 31008

Actively Recruiting

15

Hosp Clinico Univ de Salamanca

Salamanca, Spain, 37007

Actively Recruiting

16

Hosp. Univ. Marques de Valdecilla

Santander, Spain, 39008

Actively Recruiting

17

Hosp. Virgen Del Rocio

Seville, Spain, 41013

Actively Recruiting

Loading map...

Research Team

S

Study Contact

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel | DecenTrialz